Time to recurrence ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment adherence (defined as dose reduction) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (binary): definitive chemoradiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event): definitive chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Treatment adherence (defined as dose delay) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
pCR: hormone receptor‐positive · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐positive compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
pCR: hormone receptor‐negative · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐negative compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Disease-free survival · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in disease‐free survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Overall survivalmedian · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Febrile neutropenia · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in febrile neutropenia compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Diarrhoea · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pathological complete response (pCR): breast and axillary nodes compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Physical function · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Disease‐related mental health: depression · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Disease‐related mental health: anxiety · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Overall survival (time interval between enrolment in the study and death of the person from any cause) · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence‐free survival · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review